Jan 9, 2020 |
Reuters – The U.S. Food and Drug Admin. approved Blueprint Medicines Corp’s oral therapy to treat a rare form of cancer that affects the stomach and small intestine, the agency said on Thursday.
Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage.
The list price is not necessarily what patients actually pay as “out-of-pocket” costs vary based on the duration of the treatment and individual healthcare plans.
GIST tumors, which usually begin in the stomach or small intestine, are a type of soft-tissue sarcoma.
Patients are at risk of the cancer recurring even after successful surgery to remove tumors.
About 5,000 Americans are diagnosed with the cancer every year. With Ayvakit, Blueprint is looking to target about 6% of these patients whose cancers are driven by PDGFRA exon 18 mutations.
In patients with the mutation, the cancer tends to progress in about three to four months after being treated with currently available therapies … Read more.
RECENTLY:
Big Pharma Rings In 2020 With Price Hikes On 250 Rx
Price-Gouging Pharma Co. Recalls Adulterated Rx
